CDK4 and breast carcinoma: Accordingly, the combination of mTORC1 and CDK4/6 inhibitors reduces cancer cell growth more effectively and delays resistance to therapy in models of breast carcinoma, anaplastic thyroid carcinoma, and cholangiocarcinoma [118,119,120].